Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits

Journal of Vascular Research

Volumn 33, Issue 4, 1996, Pages 308-314

  Sarembock, Ian J ^a   Gertz, David ^b,c   Thome, Leonard M ^a   McCoy, Kyle W ^a   Ragosta, Michael ^a   Powers, Eric R ^a   Maraganore, John M ^a   Gimple, Lawrence W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Angioplasty; Hirulog; Rabbit model; Restenosis; Thrombin

Indexed keywords

HEPARIN; HIRULOG;

ANGIOGRAPHY; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFICACY; FEMORAL ARTERY; HISTOPATHOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; QUANTITATIVE HISTOCHEMISTRY; RABBIT; RESTENOSIS;

EID: 8944234846     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000159158     Document Type: Article

References (46)

1. Gruentzig AR, Senning A, Siegenthaler WE: Nonoperative dilation ofcoronarv artery stenosis: Percutaneous transluminal coronary angioplasty, N Engl J Med 1979:301:61-68.
2. Kent KM, Bentivoglio LG, Block PC, Cowley MK, Dorros G, Gosselin AJ, Grucntzig A, Mvl-er RK, Simpson J, Stertzcr SH, Williams DO, Fisher L, Gillespie MJ, Detre K, Kelsey S, Mul-lin SM, Mock MP: Percutaneous transluminal coronary angioplasty: Report from the registry of the NLHBI, Am J Cardiol 1982:49:2011-2018.
3. Vliestra RE, R HD, Reeder GS, Mock MB, Smith HC, Bove AA, Breshnahan JF, Pierler JM: Balloon angioplasty in multivessel coronary angioplasty, Mayo Clin Proc 1983:58: 563-567.
4. Mata LA, Bosch X, David PR, Rapold HJ, Corcos T, Bourassa MG: Clinical and angiographic assessment 6 months after double vessel percutaneous coronary angioplasty, J Am Coll Cardiol 1985;6:1239-1244.
5. Holmes DR, Vliestra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Grucntzig AR, Kelsey SF, Detre KM, Van Raden MJ, Mock MB: Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA registry of the National Heart, Lung and Blood Institute, Am J Cardiol 1984;53:77C-81C
6. Lcimgruber PP, Roubin GS, Hollman J, Cost-sonis GA, Meier B, Douglas JS, King SB, Gruentzig AR: Restenosis after successful coronary angioplasty in patients with single-vessel disease, Circulation 1986;73:710-717.
7. Liu M, Roubin G, King S: Restenosis after coronary angioplasty: Potential biological determinants and role of int imal hyperplasia, Circulation 1989;79:1374-1387.
8. Harker LA: Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty, Am J Cardiol 1987:60: 20B-28B.
9. Chesebro JH, Lam JYT, Badimcn L, Fuster V: Restenosis after arterial angioplasty, Am J Cardiol 1987;60:10B-16B.
10. Fenton JW: Thrombin: Ann NY Acad Sei 1986:485:5-15.
11. Eidt JF, Allison P, Noble S, Ashlon J, Golino P, McNatt J, Buja LM, Willerson JT: Thrombin is an important mediator of platelet aggregation in stcnosed canine coronary arteries with endothelial injury, J Clin Invest 1989:84:18-27.
12. Harmon JT, Jamieson GA: Platelet activation by alphathrombin is a receptor-mediated event, Ann NY Acad Sei 1986;485:387-395.
13. Carney DH, Glenn KC, Cunningham DD: Conditions which affect initiation of animal ccll division by trypsin and thrombus, J Cell Physiol 1978;95:13-22.
14. Gospodarowicz D, Brown KD, Birdwcll CR, Zetter BR: Control of proliferation of human vascular endothelial cells, J Cell Biol 1978:77: 774-788.
15. Chen IB, Buchanan JM: Mitogenic activity of blood components, I, Thrombin and prothrombin, Proc Natl Acad Sei USA 1975:72:131-135.
16. Buchanan JM, Chen LB, Zetter BR: Reaction of thrombin with fibroblasts and mouse spleno-cytes; in Iundblad (ed): The Chemistry and Biology of Thrombin, Ann Arbor, Ann Arbor Science Publishers, 1977. pp 519-530.
17. Martin BM, Quigley JP: Binding and uptake of thrombin: Possible role in the thrombin in duced mitogenesis of chick embryo fibroblasts; in Iundblad (ed): The Chemistry and Biology of Thrombin, Ann Arbor, Ann Arbor Science Publishers, 1977. pp 531-544.
18. Carney DH, Cunningham DD: Cell-surface action of thombin is sufficient to initiate division of chick cells, Cell 1978:14:811-823.
19. Bar-Shavit R, Kahn A, Mudd MS, Wilner GD, Mann KG, Fenton II JW: Localization of a che-motactic domain in human thrombin, Biochemistry 1984;23:397-400.
20. Cunningham DD, Farrell DH: Thrombin interactions with cultured fibroblasts: Relationship to mitogenic stimulation, Ann NY Acad Sei 1986;485:240-248.
21. Shuman MA: Thrombin-cellular interactions, Ann NY Acad Sei 1986:485:288-293.
22. Sarcmbock H. Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC: Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits, Circulation 1991;84:232-243.
23. Ragosta M, Gimple LW, Gertz SD, Dunwiddie CT, Vlasu GP, Haber HL, Powers ER, Roberts WC, Sarembock IJ: Specific Factor Xa inhibition reduces rcstenosis following ballon angioplasty of atherosclerotic femoral arteries in rabbits, Circulation 1994:89:1262-1271.
24. Sarembock IJ, LaVeau PJ, Sigal SL, Timms I, Sussman J, Haudenschild C, Ezekowitz MD: Influence of inflation pressure and balloon size on the development of intimal hyperplasia after balloon angioplasty: A study in the atherosclerotic rabbit, Circulation 1989:80:1029-1040.
25. Kritchevsky D, Tepper SA, Kim HK, Story JA, Vesselinovitch D, Wissler RW: Experimental atherosclerosis in rabbits fed cholcsterol-free diets: Comparison of peanut, com, butter, and coconut oils, Exp Mol Pathol 1976:24:375-391.
26. Owen RM, Dewey JD, Bove AA: Evaluation of dimensions and steady-state hydraulic properties of coronaries, Proc Annu Rocky Mountain BiocngSymp 1983;19:43-46.
27. Movat H: Demonstration of all connective tissue elements in a single section, Arch Pathol Lab Med 1955;60:289-295.
28. McNamara CA, Sarcmbock IJ, Gimple LW, Fenton IJ, Coughlin SR, Owens GK: Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor, J Clin Invest 1993:91:94-98.
29. Ragosta M, Barry WL, McCoy KW, Gimple LW, Souffer GA, McNamara CA, Powers ER, Owens GK, Sarembock IJ: Early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits, Clin Res 1994:42: 180A.
30. Post M, van Erven L, Vclema E, Bentala M, Borst C: Which part of the angiographic diameter reduction after balloon dilation is due to intimal hyperplasia? J Am Coll Cardiol 1993: 2 (suppl A):36A.
31. Post M, van Ervan L, Valema E, Borst C: Re-stenosis is partly due to intimal hyperplasia and partly due to remodeling of the injured arterial wall, Eur Heart J 1993:14(suppl): 201 A.
32. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP: Differences in compensatory vessel enlargement, not intima formation, account for rcstenosis after angioplasty in the hypcrcholesterolcmic rabbit model, Circulation 1993;89:2809-2815.
33. Maraganore JM, Bourdon P, Jablonski J, Ra-machandran KL, Fenton JW: Design and characterization of hirulogs: A novel class of a-thrombin, Biochemistry 1990:29:7095-7101.
34. Skrzypczak-Jankun E, Carperos VE, Ravichan-dran KG, Tulinsky A, Westbrook M, Maraganore JM: Structure of the hirugen and hirulog I complexes of alpha-thrombin, J Mol Biol 1991: 221:1379-1393.
35. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: C'lot-bound thrombin is protected from inhibition by heparin-ant¡thrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors, J Clin Invest 1990:86:385-391.
36. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL: Anticoagulant activity of synthetic hirudin peptides, J Biol C'hcm 1989:264:8692-8698.
37. Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA: Antithrombotic effects of synthetic peptides targeting various domains of thrombin, Proc Natl Acad Sei USA 1992:89: 6040-6044.
38. Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E: Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease, Am J Cardiol 1993:71:778-782.
39. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kak-kar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J: Use of a direct anti-thrombin, hirulog, in place of heparin during coronary angioplasty, Circulation 1993:87: 1622-1629.
40. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Marganore J, Deutsch F, Adelman B, for the Hirulog Angioplasty Study Investigators: Treatment with bi-valirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina, N Engl J Med 1995:333: 757-763.
41. Serruvs PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, Van Kijk R, Van Den Bos A, Umans VAWM, Fox KAA, Close P, DeckersJW, for the HELVETICA investigators: A comparison of hirudin with heparin in the prevention of rcstenosis after coronary angioplasty, N Engl J Med 1995:333:764-769.
42. Fox I, Dawson A, Loynds P, Eisner J, Findlcn K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J: Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans, Thromb Haemost 1993:69:157-163.
43. Rapold HJ, de Bono D, Arnold AER, Armout J, Dc Cock F, Collen D, Vcrstraete M: Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplasc, Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia, Circulation 1992:85:928-934.
44. Rapold JH, Kucmmerli H, W'ciss M, Bauer H, Haeberli A: Monitoring fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissuc-tvpc plasminogen activator, Circulation 1989:79:980-989.
45. Hsia J, Kleiman N, Aguirre F, Chaitman B, Roberts R, Ross AM: Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relationship to coronary patency, J Am Coll Cardiol 1992;20:31-35.
46. Hirsh J: Heparin, N Engl J Med 1992:324: 1565-1574.